Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.62 and traded as low as $1.36. Pulmatrix shares last traded at $1.3950, with a volume of 7,375 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Pulmatrix presently has an average rating of “Sell”.
Read Our Latest Research Report on PULM
Pulmatrix Trading Down 2.4%
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.00) by $1.71.
Institutional Trading of Pulmatrix
Hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP acquired a new stake in shares of Pulmatrix during the third quarter worth approximately $52,000. DRW Securities LLC bought a new stake in Pulmatrix during the fourth quarter worth approximately $46,000. Finally, BlackRock Inc. bought a new stake in shares of Pulmatrix during the 2nd quarter worth $93,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.
Pulmatrix Company Profile
Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.
Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).
Featured Articles
- Five stocks we like better than Pulmatrix
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
